Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotechnology filing packed with enzyme pathways and Phase 2 endpoints can feel like decoding a new language. Galectin Therapeutics’ documents add another layer of complexity by detailing how carbohydrate polymers blunt galectin-3 to slow liver fibrosis. If you have ever searched for “Galectin Therapeutics SEC filings explained simply” or wondered where the “Galectin Therapeutics quarterly earnings report 10-Q filing” hides cash-burn clues, you know the challenge.
Stock Titan turns that challenge into clarity. Our AI instantly extracts trial timelines, financing terms, and risk factors from every 10-K and 10-Q, giving you a “Galectin Therapeutics annual report 10-K simplified” in minutes. Real-time alerts flag each “Galectin Therapeutics 8-K material events explained,” while concise dashboards track “Galectin Therapeutics insider trading Form 4 transactions.” Need to monitor management confidence? We surface every “Galectin Therapeutics executive stock transactions Form 4” as soon as they hit EDGAR, along with context that links trades to upcoming liver-fibrosis data releases.
Whether you are comparing R&D spend trends, scanning the “Galectin Therapeutics proxy statement executive compensation,” or seeking “Galectin Therapeutics earnings report filing analysis,” our platform keeps biotech nuance front and center. AI-powered summaries translate statistical jargon into everyday language, highlight non-cash charges, and point to footnotes on trial enrollment hurdles—so understanding Galectin Therapeutics SEC documents with AI becomes part of your routine, not an all-night project. All filings, all forms, always up to date, with “Galectin Therapeutics Form 4 insider transactions real-time” monitoring just a click away.
Galectin Therapeutics (GALT) filed its definitive proxy for the 2025 annual meeting, which will be held virtually on December 3, 2025 at 11:00 a.m. EST via www.virtualshareholdermeeting.com/GALT2025. Holders of Common Stock or Series A 12% Convertible Preferred Stock of record as of October 7, 2025 may vote.
Stockholders will vote on: (1) electing 11 directors, (2) a non-binding “say‑on‑pay” advisory resolution, (3) a non-binding vote on the frequency of say‑on‑pay, and (4) ratification of Cherry Bekaert LLP as independent auditor for fiscal 2025. The Board recommends FOR all proposals and recommends say‑on‑pay votes occur every three years.
Directors and executive officers control voting for approximately 19% of outstanding voting shares and expect to vote FOR all items. Shares outstanding for quorum purposes were 64,479,210 as of the record date. The proxy also details related‑party financing with Richard E. Uihlein, including prior convertible notes (conversion prices $5.00, $8.64, and $5.43), lines of credit up to
Galectin Therapeutics (GALT) filed a Form 5
The reporting person is marked as a Director, with holdings reported as indirect through 10X Fund, L.P. The disclosure notes that 10X Capital Management, LLC is the general partner of 10X Fund, L.P. and may be deemed to have indirect beneficial ownership, while disclaiming beneficial ownership except to the extent of pecuniary interest.
Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics Inc. (GALT), reported transactions on Form 4 showing the exercise and sale of common stock on 09/12/2025. The filing discloses the exercise of 8,706 stock options with an exercise price of $1.37 (options originally granted 01/20/2019 and expiring 01/20/2026). Those 8,706 shares were sold the same day under a Rule 10b5-1 plan adopted April 17, 2025, at a weighted average price of $6.4385 (sales ranged $6.33–$6.68). After these transactions the reporting person beneficially owned 7,614 shares, down from 16,320 prior to the transactions. The filing includes an undertaking to provide per-trade sale details on request.
Joel Lewis, President and CEO of Galectin Therapeutics (GALT), reported option exercise and share sale transactions on 09/12/2025. He exercised a stock option with a $2.39 exercise price to acquire 14,000 shares and contemporaneously sold 14,000 shares at a weighted average price of $6.3606, resulting in reported beneficial ownership of 846,592 shares after the acquisition and 832,592 shares after the sale. The option exercised was part of a grant exercisable since 12/14/2018 and expiring 12/14/2027. The filing notes these transactions were made pursuant to a Rule 10b5-1 trading plan adopted April 17, 2025. Mr. Lewis also reports 2,000 shares held indirectly as custodian for a minor, which he disclaims as beneficially owned.
Galectin Therapeutics Inc. furnished a Current Report on Form 8-K on August 14, 2025 announcing its results of operations and financial condition for the six months ended June 30, 2025 and providing a business update. The company incorporated by reference a press release dated August 14, 2025 filed as Exhibit 99.1 and included an interactive cover page XBRL as Exhibit 104. The filing notes that the press release contains forward-looking statements subject to risks described in Galectin's Annual Report for the year ended December 31, 2024. The information in Item 2.02 is furnished, not filed.
Galectin Therapeutics reported cash of $13.771 million and a six-month net loss of $17.152 million. Operating expenses for the six months fell to $12.522 million from $20.939 million a year earlier, driven by lower research and development spending ($9.746 million versus $17.867 million). Net cash used in operating activities improved to $14.291 million from $20.438 million. The balance sheet shows total liabilities of $132.769 million and stockholders' deficit of $(118.890 million), including $88.150 million of borrowings and accrued interest under related-party convertible lines of credit and $1.537 million of derivative liabilities. Management discloses substantial doubt about the company’s ability to continue as a going concern but states available credit and a new related-party $10 million supplemental line provide belief that planned operations can be funded through June 30, 2026.
FAQ
What is the current stock price of Galectin Therapeutics (GALT)?
What is the market cap of Galectin Therapeutics (GALT)?
